TABLE 1

Plasma lipids and hepatic PEPCK activity in STZ-exposed Wistar rats treated with the DP IV inhibitor P32/98

ControlSTZ controlEarly treatmentLate treatment
PEPCK (mU/kg)22.7 ± 1.746.3 ± 4.3††24.2 ± 2.4*35.9 ± 4.8
Triglycerides (mmol/l)0.50 ± 0.142.37 ± 0.28††0.94 ± 0.11**1.61 ± 0.22*††
NEFAs (mmol/l)0.28 ± 0.040.52 ± 0.05††0.24 ± 0.03*0.41 ± 0.02††
Cholesterol (mmol/l)1.59 ± 0.162.53 ± 0.311.54 ± 0.10*1.75 ± 0.12*
  • NEFAs, nonesterified fatty acids. Statistical significance vs. STZ controls is indicated by

  • *

    * (P < 0.05) or

  • **

    ** (P < 0.01) and vs. controls by

  • (P < 0.05) or

  • ††

    †† (P < 0.01).